Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  brain tumor
Stage/Subtype:  brain tumor
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-16 of 16 for your search:
Start Over
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
Vaccine Therapy with Bevacizumab or Bevacizumab Alone in Treating Patients with Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A071101, NCI-2013-00444, NCT01814813
ERC1671/GM-CSF/Cyclophosphamide in Treating Patients with Relapsed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ERC1671-H02, NCI-2014-00737, 11922, ERC1671, UCI 13-14, NCT01903330
Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00054740, NCI-2015-00856, NCT02366728
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259614, NCI-2015-00694, NCT02455557
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ICT-121 DC-01, NCI-2015-01976, NCT02049489
Vaccine Therapy and Temozolomide in Treating Patients with Recurrent Glioma Expressing IDH1
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00054746, NCI-2015-02213, NCT02193347
Vaccine Therapy and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-362, NCI-2014-02645, NCT02287428
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI-DSP7888-101, NCI-2015-01357, NCT02498665
Nivolumab with or without Vaccine Therapy in Treating Patients with Recurrent Brain Tumors Undergoing Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: Pro00065241, NCI-2016-00059, NCT02529072
Imiquimod and Vaccine Therapy in Treating Younger Patients with Recurrent or Progressive Glioblastoma Multiforme or Diffuse Intrinsic Pontine Glioma
Status: Temporarily closed
Phase: No phase specified
Type: Treatment
Age: 3 and over
Trial IDs: 2009LS136, NCI-2012-00322, CPRC #2009LS136, HSC # 1004M81213, NCT01400672
Vaccine Therapy and Imiquimod in Treating Patients With High Risk or Recurrent Grade II Gliomas
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 11-136, NCI-2013-00078, NCT01678352
Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Status: Temporarily closed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1272, NCI-2013-01743, NCT01957956
Neoantigen-based Glioblastoma Vaccine and Poly-ICLC Vaccine in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201510022, NCI-2015-01776, NCT02510950
Start Over